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Objectives: This study investigated current influenza vaccination rates among 
the urban Chinese population and high-risk adults. MethOds: This study included 
data from the 2013 China (N= 19,987) National Health and Wellness Surveys (NHWS), 
a cross-sectional, Internet-based survey. The NHWS includes a sample of urban (Tier 
I and II cities) adults (≥ 18 years) which included items on vaccination history and 
high-risk status defined by the World Health Organization(WHO). Vaccination rates 
and characteristics of vaccinees were reported descriptively. Logistic regressions 
were conducted to predict vaccination behavior from sociodemographics and risk-
related variables. Results: Only 13.69% of adults in urban China reported being 
vaccinated for influenza in 2013. Among patients in high-risk groups (coronary heart 
disease [CHD], chronic lung conditions etc.), vaccination rates were low for most 
groups, ranging from 5.7% (≥ 65 years) to 57.69% (chronic neurological conditions). 
The most common reason for non-vaccination was belief that it was not needed 
(17.8%); other common reasons for non-vaccination included believing that the vac-
cine is not effective (12.9%) and not getting a vaccine before (9%). Respondents who 
were vaccinated were less likely to be older (OR= 0.982), currently married (OR= 0.792) 
and university educated (OR= 0.748), and more likely to be female (OR= 1.403), 
a current smoker (OR= 1.387) exercised more on average (OR= 1.023), consumed alco-
hol regularly (OR= 2.299), feared needles more (OR= 1.111), and had higher incomes 
(RMB6,000 or more) (OR= 1.62) compared with those not vaccinated. The strongest 
predictors of vaccination were having CHD (OR= 2.161), chronic lung (OR= 2.069), 
chronic liver (OR= 1.891), chronic metabolic condition (OR= 1.835), or chronic renal 
conditions (OR= 1.758)(all p< .05). cOnclusiOns: Overall vaccination rates were low 
in China. Most WHO-recommended vaccination groups had rates less than 20% and 
a large gap remains between these recommendations and vaccination behavior. In 
2011, the influenza vaccination rates among adults in the United States were 36.2%, 
almost three times the vaccination rate in urban China.
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Objectives: Infection control and its Prevention system were established and 
its role, responsibility and right were clarified in Mongolia in May 4, 2010 by the 
decree of Minister of Health “Strengthening infection control system of Health 
care organizations and intensifying preventive actions of Hospital infections”. The 
Goal of this study is to implement a guideline for evaluation and development of 
Infection control and its Prevention activities of all levels of health care organiza-
tions. MethOds: 1. Method of cross sectional study was used in research of cur-
rent condition of Infection control Department activities. 2. Disinfection quality 
and safety was studied by Retrospective and Description methd. 3. Knowledge of 
disinfection and hand washing ofmedical staff are studied by descriptive and cross-
sectional study. Results: Assessment of current condition for activity of Infection 
control Department in national level was conducted among 6 tertiary level hospi-
tals, 8 secondary level hospitals and 28 primary level hospitals. cOnclusiOns: 
1. Infection control for department and teams at health care organizations work 
with proper structure of management and members, and their activities vary 
according to its level. 2. The health care organization’s hygiene standards and condi-
tions are different, especially disinfectants and equipment are inadequate. Medical 
stuff’s ability to hand disinfection is reduced according to its level. 3. Sterilizing 
quality is good enough, but its initial test and monitoring by technical methods are 
insufficient in primary health facilities. 4. 80.4% of medical staff attended infection 
control training and have adequate knowledge of hospital infections.
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Objectives: Globally, human immunodeficiency virus/acquired immune deficiency 
syndrome (HIV/AIDS) reduces life expectancy by several years. Mortality is high 
among non-treated patients. However, the predictors of mortality have not been 
adequately studied. Hence, the main objective of the study was to determine predic-
tors of mortality among HIV positive adults who are not on antiretroviral treatment, 
in a South Indian hospital. MethOds: A facility-based retrospective cohort study 
was conducted and data were collected from 150 patients who were registered 
but not on treatment from December 2011 to December 2013. Multiple logistic 
regression analysis was applied to identify the risk factors for mortality among 
HIV patients. Results: A total of 40 patients were died during the follow-up period. 
Patients with age between 39-59 years (OR 0.49, 95% CI 0.28-0.84), baseline World 
Health Organization (WHO) staging III and IV (OR 0.09, 95% CI 0.04-0.20 and OR 0.11, 
95% CI 0.04-0.27), patients with opportunistic infections (OR 4.93, 95% CI 2.87-8.84), 
were found to have less risk for mortality compared to their counterparts. Patients 
with low BMI (OR 2.05, 95% CI 1.21-3.49), CD4 count > 200 cells/µl (OR 3.88, 95% CI 
2.27-6.65) were found to have more risk. cOnclusiOns: Age group 18-38, patients 
without opportunistic infections, baseline WHO staging stage I and II, low BMI, CD4 
> 200 cells/µl were all significant predictors of mortality.  Therefore, patients with the 
aforementioned predictors should be followed closely and frequently.
INfectIoN – cost studies
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individuals or have no recommendations. The annual incidence of varicella in the 
general populations ranged from 13.7 to 76 per 100,000 in Asia-Pacific countries 
with universal vaccination, and from 100 to 512 per 100,000 in Asia-Pacific countries 
without universal vaccination. Studies in China, Japan, and South Korea showed 
varicella incidence peaking in spring and winter. Limited publication has reported 
varicella-related mortality in the Asia-Pacific region. Majority of the studies assess-
ing health care resource utilization focused on inpatient care. The most frequent 
complications among hospitalized patients were skin and respiratory complications. 
Hospitalization rates associated with varicella reported in Australia and Taiwan 
were 0.11 and 60 per 1,000 cases, respectively. Medical costs associated with varicella 
were estimated in China, Japan, Singapore, Taiwan, and Australia. cOnclusiOns: 
Epidemiology and economic burden of varicella in Asia-Pacific countries have not 
been extensively studied. Given limited varicella vaccination policy in this region, 
gaps in evidence need to be addressed to inform policy makers about the public 
health impact of varicella.
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Objectives: Influenza vaccination rates have not been high enough in Japan. This 
study investigated current influenza vaccination rates among the general Japan 
population and rates among high-risk adults. MethOds: This study included data 
from the 2011-2012 Japan (Ns= 30,000) National Health and Wellness Surveys(NHWS) 
a cross-sectional, Internet-bases survey.  The NHWS includes a nationwide sample 
of adults (18+ years) which included items on vaccination history as well as high-
risk group status as defined by the World Health Organization(WHO). Vaccination 
rates and characteristics of vaccinees were reported descriptively. Logistic regres-
sions were conducted to predict vaccination behavior from sociodemographics and 
risk-related variables. Results: 17.17% of adults in Japan reported being vaccinated 
for influenza in 2012(compared with 19.17% in 2011). Even among patients in high-
risk groups(CHD, chronic lung conditions etc.), vaccination rates were low, ranging 
from 24.83%(caregivers) to 42.86%(patients with immunodeficiencies). The most 
common reason for non-vaccination was the belief that it was not important(45.3%); 
other common reasons included believing that the vaccine is not effective (13.0%) 
and that prior infection leads to future resistance(12.3%). Respondents who were 
vaccinated were more likely to be female (OR= 1.006), older(OR= 1.212), univer-
sity educated(OR= 1.225), and employed(OR= 1.242) with higher incomes(¥5MM 
or more) (OR= 1.128) when compared to those who did not receive the vaccine. 
Those vaccinated also exercised more on average(OR= 1.006), and feared needles 
less(OR= 0.869). The strongest predictors of vaccination were having an immuno-
deficiency (OR= 3.613), heart disease (OR= 2.571), chronic lung(OR= 2.025), chronic 
liver(OR= 1.625), chronic renal condition(OR= 1.608) or chronic metabolic conditions 
(OR= 1.532) (all p< .05). cOnclusiOns: Overall vaccination rates were low in Japan 
with no increase in vaccination rates from the prior year. All WHO-recommended 
vaccination groups had rates less than 50% and a large gap remains between these 
recommendations and vaccination behavior. In 2011, the influenza vaccination 
rates among adults in the United States were 36.2%, almost twice the vaccination 
rate in Japan.
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Objectives: To assess the prevalence of health care-associated infection (HAI) 
in 2012 among grade A hospitals in China. MethOds: Literatures were searched 
from PubMed, EMBASE, Cochrane Library, CNKI, cqvip, WANFANG, and SinoMed 
from Jan. 2012 to Mar. 2014. Literatures were screened and data was extracted by 
two independent reviewers, separately. Meta-analyses were conducted by R3.0.3 
with random effect models. Results: Fifty studies with 91,763 patients met the 
inclusion criteria and were included. The overall prevalence rate of HAI among all 
studies was 3.4% (95% CI: 3.1%-3.8%). Among the 50 studies, 25 were performed in 
Grade A tertiary hospitals and the rest 25 in grade A level 2 hospitals. The 25 studies 
performed in Grade A tertiary hospitals including 26,700 participants reported the 
pooled HAI prevalence as 3.5% (95% CI: 3.0%-4.1%). The aggregated HAI prevalence 
of the other 25 studies with 65,063 patients in grade A level 2 hospitals was 3.2% 
(95% CI: 2.7%-3.8%), which was not significantly different from that in Grade A 
tertiary hospitals (P= 0.32). In the analyses of different infection sites, 18 studies 
targeting at lower respiratory infection (19,035 participants) revealed the highest 
combined constituent ratio as 46.6% (95% CI: 40.1%-52.3%). The pooled constituent 
ratio of 17 studies targeting at urinary system infection (19,949 participants) was 
16.1% (95% CI: 11.5%-22.1%) and that of 19 studies targeting at upper respiratory 
infection (20,924 participants) was 15.2% (95% CI: 11.2%-20.2%). In the analyses of 
antibiotics using, 18 studies were identified (19,090 participants) in grade A ter-
tiary hospitals and revealed pooled antibiotics using ratio as 42.96% (95% CI: 38.3%-
47.8%). cOnclusiOns: The aggregated prevalence rate of HAI was 3.4% across all 
general hospitals. The pooled prevalence rate among grade A tertiary hospitals and 
grade A level 2 hospitals showed no significant difference. Among all infection sites, 
lower respiratory infection accounts for the highest proportion.
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amounted to 178 514 euro. The average hospitalisation costs per patient was 2380 
euro. cOnclusiOns: Our analysis demonstrates that therapies of drug-induced, 
adverse skin reactions induced by antibiotics generate considerable costs, both for 
the payer and the service provider. The costs, which are incurred by either party, 
are comparable, providing evidence that the pricing of procedures, proposed by the 
public payer in Poland and valid since 2012, has been adequate to the expenses, 
borne by the service provider.
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Objectives: Through analyzing the main immunization strategies for preventing 
mother-to-child transmission of HBV in China, figure out the optimized strategy 
which fit the current situation of China based on constructed Decision Tree-Markov 
model and cost-benefit analyses. MethOds: The multilevel decision tree-markov 
model was constructed by TreeAge Pro Software 2011, which could simulate the 
prognosis of HBV disease after various immunization strategies for preventing 
mother-to-child transmission of HBV; In this model, extracted parameters were 
needed, including vaccine inoculation rate, protective rate of various immuniza-
tion protocol, the prognosis of disease and its probabilities, the financial burden 
of various disease condition, from important published researches by literature 
review; then evaluated each immunization strategy by cost-benefit analyses, and 
examined the stability of test results, the parameters which influence the results 
greatly through sensitivity analysis and threshold analysis. Results: Currently 
there were 8 immunization strategies for preventing mother-to-child transmission 
of HBV in China. The cost of each immunization strategy varied from 8162.8 RMB 
(1316.6US$) to 14840.4 RMB(2393.6US$), which included the vaccine inoculation and 
infection and therapy cost if immunization failed. The benefit of each strategy, 
which was assessed by the avoiding financial burden by immunization, varied from 
50801.9 RMB (8193.8US$) to 73801.0 RMB (11903.4US$). The BCR of each strategies 
varied from 3.7 to 19.3. The sensitive factors were vaccination protection rate, vac-
cination inoculation rate, the costs of HBV infection every year. cOnclusiOns: 
Comparatively, the optimized strategy in China was giving the newborns of HBsAg 
positive mother an 200IU HBIG IM injection within 24 hrs after birth, then 3 shots 10 
μ g Hepatitis B Vaccine in accordance with 0-1-6 procedure (BCR= 19.3). The decision 
tree -Markov model has good applicability and reliability for quantitative economic 
evaluation and optimization of hepatitis B vaccination strategies for preventing 
mother-to-child transmission.
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Objectives: To evaluate published cost-effectiveness analyses (CEA) assessing 
nucleos(t)ide analogues (NAs), interferon, and pegylated interferon for chronic 
hepatitis B (CHB). MethOds: Main medical databases in both English and Chinese 
were searched up to October 2012 to identify eligible studies for data extraction. 
The base case incremental costeffectiveness ratio (ICER) per quality-adjusted 
life year (QALY) was adjusted to 2011 local currency value and presented by the 
ratio to 2011 gross domestic product per capita (GDPPC). Simple linear regression 
analyses took adjusted ICER per QALY as dependent variable to assess the cost-
effectiveness of antiviral therapy when compared to lamivudine. Results: 81 
studies published in English and 18 studies published in Chinese were identified. 
When compared to no treatment, all NAs were associated with an ICER per QALY 
of less than 1 GDPPC in high or middle-income countries. When compared to 
lamivudine, entecavir was associated with an ICER per QALY of less than 1 GDPPC 
in high or middle-income countries. Simple linear regression analyses observed 
significantly reduced ICER per QALY associated with entecavir (coefficient -1.450, 
P= 0.018) but significantly increased ICER per QALY associated with interferon 
(coefficient 5.583, P< 0.001) or adefovir (coefficient 2.354, P< 0.001) when compared 
to lamivudine. Telbivudine, tenofovir and pegylated interferon did not have sig-
nificant impact on ICER per QALY when lamivudine was the reference. One study 
published in Chinese was considered high quality and reported the lowest ICER 
per QALY associated with entecavir when compared to no treatment in patients 
with positive or negative hepatitis B e antigen (HBeAg). cOnclusiOns: When 
compared to no treatment, NAs were highly cost-effective for CHB in high or 
middle-income countries. When compared to lamivudine, entecavir was the most 
cost-effective treatment among NAs. Entecavir was also the most cost-effective 
NA when compared to no treatment in Chinese patients with CHB, irrespective 
of their HBeAg status.
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Objectives: The Pneumococcal disease is a major cause of morbidity and mortal-
ity in pediatrics, and it leads to serious health as well as economic burden on the 
national health care system. In Korea, both 13-valent and 10-valent pneumococcal 
conjugate vaccines are currently used for the prevention of pneumococcal infec-
tions for Pediatrics. This study aims to evaluate the long-term economic and clini-
cal impact of PCV-13 versus PCV-10 vaccination in prevention of IPD, pneumonia 
and acute otitis media (AOM) from health care system perspective. MethOds: 
A Markov cohort model with a 10-year time horizon was used to estimate the effect 
of infant vaccination with PCV-13 versus PCV-10. Using this model, we considered 
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Objectives: To compare clinical outcomes and hospital costs in patients receiving 
empirical treatment of hospital-acquired pneumonia (HAP) with vancomycin or lin-
ezolid in Chinese patients. MethOds: Patients receiving empirical treatment with 
vancomycin or linezolid for HAP from 2008 to 2012 in a tertiary hospital in Shanghai 
were identified and linked with hospital administration databases for retrospective 
data extraction. Best matching pairs identified by propensity score methods for 
the two antibiotics were compared on HAP-related clinical response, in-hospital 
mortality, and allocation of hospital costs. The comparisons on clinical outcomes 
were confirmed by multiple logistic regression analyses with adjusting unbalanced 
baseline variables between matched pairs. Results: 60 propensity score matched 
pairs for the two antibiotics were identified. Empirical treatment with vancomycin 
or linezolid had comparable responses at the end of treatment (clinical cure: 30.0% 
vs. 31.7%, p= 0.847; treatment failure: 55.0% vs. 45.0%, p= 0.289). However, vanco-
mycin was associated with significantly lower in-hospital mortality than linezolid 
(3.3% vs. 18.3%, p= 0.013). Comparable risk of treatment failure between the two 
antibiotics (odds ratio (OR) 1.139, p= 0.308) and lower risk of in-hospital mortality 
associated with vancomycin (OR 0.186, p= 0.055) were confirmed after adjustment 
of unbalanced baseline variables between matched pairs. Vancomycin was associ-
ated with lower total hospital costs than linezolid (RMB 113,160 vs. RMB 133,825, 
p= 0.076; 1 RMB = 0.16 US dollars) likely because of significantly lower acquisition 
cost of vancomycin (median RMB 2,880 vs. RMB 8,194, p< 0.001) and other hospital 
costs unrelated to drugs, medical examinations, and medical supplies (median RMB 
27,686 vs. RMB 44,826, p= 0.006). cOnclusiOns: Empirical treatment with vanco-
mycin and linezolid for HAP had comparable treatment response but in-hospital 
mortality associated with vancomycin was lower in Chinese patients. Significantly 
lower antibiotic acquisition cost and other hospital costs unrelated to drugs, exams, 
and supplies likely made substantial contribution to the reduced hospital costs 
associated with vancomycin.
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Objectives: Incidence of hepatitis C viral infection (HCV) is increasing in China 
and HCV represents considerable disease burden to the country. As there is no 
published data on treatment costs to HCV in China, this study reports key findings 
from a recent survey to examine treatment costs in the country. MethOds: A cross 
sectional survey was conducted in 2012 among 29 hospitals across China. Data were 
collected from patients who visited either outpatient or inpatient settings, including 
patient demographics, coverage of health insurance, and costs to treat HCV related 
visits. Results were analyzed by descriptive statistics. Results: A total of 1,116 
patients participated into this survey. Males (52.6%) were slightly more than females. 
The average age was 45.5 years old and 49.9 years old for outpatient and inpatient 
cases, respectively. Patients who were in their productive age groups (30 to 49 years 
old) are the majority (48.7%). While most of the inpatient cases had health insurance 
coverage, 49.6% of the outpatient cases were out of pocket. Medium cost for an HCV 
related hospital admission was 8,212 RMB (or 1,369 USD); of which medications, 
both western and traditional medicines, cost 61.1%. This study found that 
more advanced the disease progress, higher costs to the condition: for chronic 
HCV, cirrhosis, and hepatocellular carcinoma, the medium costs were 8,111 
RMB (1,351 USD), 8,399 RMB (1,399 USD), and 14,425 RMB (2,404 USD), respec-
tively. cOnclusiOns: Key findings suggest that (1) a better disease management 
strategy help to improve the national economy in long term; (2) the needs for an 
early and successful treatment to these patients to reduce the finance burden; and 
(3) an improvement of health policy, especially on health insurance, would result 
in better treatment and disease management to HCV in China.
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Objectives: The aim was to analyze the direct costs of treatment of skin drug 
reactions induced by antibiotics in perspective of public payer (National Health 
Fund) and service provider. MethOds: We analyzed retrospectively data from 164 
patients hospitalized in the Department of Dermatology, Military Medical Institute 
in Warsaw (from 2002 to 2012) due to skin drug reactions. The analysis was based 
on data derived from the patients’ medical charts and cost data provided by the 
hospital accounting department. The hospitalization costs by National Health 
Fund (NHF) were calculated based on the prices for medical services established 
by the NHF on the basis of a contract with the Military Institute of Medicine (2012 
year). Results: In the study group the most common cause of cutaneous drug 
reactions were antibiotics (45 %) including beta lactamase antibiotics, antibiotics 
with beta-lactamase inhibitor, clindamycins, flourochinolons. The total cost of hos-
pitalisation, based on the scores, assigned by the National Health Fund was 177 629 
euro. The average cost per patient was 2368 euro. The total costs of hospitalisation 
in the analysed period, incurred by the Military Institute of Medicine and calculated 
according to the internal pricelist for the year 2012 for the analysed study group 
